Company profile
Amplo Biotechnology company profile
Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program, AAV-Dok7, was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases.
Business identity
- Contact email
- [email protected]
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Revenue range
- $0-$1M
- Founded
- 2019-01-01, Year
Headquarters
- Headquarters
- San Diego, California, United States
- Postal code
- 92037
- Country code
- US
- Continent
- North America